Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (APERTO OTW®) for Arteriovenous Fistulae Stenosis: a Prospective, Multicenter, Randomized Controlled Trial APERTO AVF China

**Qizhuang Jin** 

Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China

## **PTA and Surgery**

#### Table II. Endovascular treatment of thrombosed fistulae

First author, year	No.	Location AVF		Technica success	Patency (1 yr)	
			Modality		Primary	Secondary
Overbosch, 1996	24	24 forearm	Mechanical thrombectomy	89%	32%	100
Turmel-Rodrigues, 2000	73	56 forearm 17 upper arm	Thromboaspiration $\pm$ urokinase	93%	49% 9%	81% 50%
Haage, 2000	54	50 forearm 4 upper arm	Mechanical thrombectomy	89%	27%	51%
Schon, 2000	20		Mechanical thrombectomy + tPA	92%	325.15	
Liang, 2002	42	37 forearm 5 upper arm	Angioplasty ± urokinase	93%	70%	80%
Rajan, 2002	25	19 forearm 6 upper arm	Mechanical thrombectomy + urokinase, tPA	73%	24%	44%
Bittl, 2005	39	and the second second	Mechanical thrombectomy	87%	23%	31 - 10 - 10 - 10 - 1
Shatsky, 2005	62	24 forearm 36 upper arm 2 leg	Thromboaspiration $\pm tPA$	87%	18%	69%
Moossavi, 2007	49	23 forearm 26 upper arm	Mechanical thrombectomy	96%	$51\% \\ 47\%$	84% 62%
Jain, 2008	41	21 forearm 20 upper arm	Mechanical thrombectomy	76%	20%	54%
Wu, 2009	48	48 forearm	Mechanical thrombectomy	96%	44%	89%

### Table III. Surgical treatment of thrombosed fistulae

First author, year	Nø.	Location AVF		Technical	Patency (1 yr)	
			Modality	success	Primary	Secondary
Oakes. 1998	29	29 forearm	Proximal reanastomosis	80%	69%	89%
Morosetti, 2002	26	17 forearm 9 upper arm	Thrombectomy ± proximal reanastomosis	82% 66%	93% (6 mon) 84%	* * *
Mickley, 2003	30	30 forearm	Proximal reanastomosis	100%	80%	95%
Ponikvar, 2005	268	1.111	Thrombectomy ± proximal reanastomosis	93%	75%	77%
Georgiadis, 2005	59	59 forearm	Thrombectomy ± Graft interposition	95%	10100	85%
Palmar, 2006	10	3 forearm 7 upper arm	Thrombectomy	70%	51%	69
Lipari, 2007	32	32 forearm	Proximal reanastomosis or graft interposition	84%	73%	88%

### **Restenosis after PTA**

- Clinically significant restenosis is generally defined as target lesion 50% or greater restenosis after technically successful PTA
- The prevalence of restenosis after PTA is unclear as there wasn't large-scale epidemiological investigations. Different studies showed the 6-month primary patency rate of dialysis grafts tended to be 36%-76%, and only 17%-48% and 26%–58% of AVGs and native AVFs remain functional without subsequent interventions at 12 months respectively

Portugaller RH, et al. J Vasc Access. 2014 Nov-Dec;15(6):439-47. Neuen BL, et al. J Vasc Interv Radiol. 2014 Jun;25(6):917-24.

### The Combat against Restenosis

### Drug Coated Balloons (DCB)

- DCBs are coated with paclitaxel. In experimental studies, even very low single doses of paclitaxel have exhibited a sustained anti-proliferative effect on VSMCs
- DCBs are routine therapy in the treatment of restenosis after percutaneous coronary interventions (PCIs)
- More and more researchers focused on the DCBs usage in the treatment of hemodialysis access stenosis since 2012, and clinical results to date are encouraging

# Published studies reporting the results of DCB for AV stenosis

Year	Design	No. of patients (no. of lesions)	Stenosis localization	Primary end point	Main results, DCB vs uncoated balloon
2012 <sup>1</sup>	Randomized, unicenter	40 (40)	Venous (NS)	PP at 6 m	70% v 25% ( P< .001)
2014 <sup>2</sup>	Randomized, unicenter	10 (20)	JAS: 10/20 Venous: 10/20	TLR at 6 m	70% v 0% (P< .01)
2015 <sup>3</sup>	Randomized, unicenter	40 (40)	JAS: 25/40 Venous: 15/40	TLR-free survival at 12 m	308 v 161 days (P< .039)
2014 <sup>4</sup>	Retrospective unicenter	26 (26)	Venous (NS)	PP and SP at 1 y and 2 y	1-year PP: 20/22 (90.2%) 2-year PP: 11/29 (57.8%) 1-year SP: 20/20 (100%) 2-year SP: 18/19 (94.7%)


1. J Endovasc Ther. 2012;19:263–272 2. J Vasc Interv Radiol 2014; 25:535–541 3. Eur J Radiol 2015, 84: 418–423 4. J Vasc Access 2014;15: 338-343

## APERTO OTW<sup>®</sup> is specifically designed for AV stenosis

	Aperto	Lutonix	In.Pact Admiral	In.Pact Pacific
Drug	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel
Dose Density	3.0 µg/mm²	2.0 µg/mm²	3.5 µg/mm²	3.5 µg/mm²
Excipient	Ammonium Salt	Polysorbate and sorbitol	Urea	Urea
	Low hydrophilic Elastic film	Highly Hydrophilic	Highly Hydrophilic	Highly Hydrophilic
Particle size	0.1 μm	2 µm	3 µm	3 µm
Shaft Length	<b>40 cm</b> Except 9&10mm (80 cm)	80 cm	40 cm	80 cm
High pressure	<b>Yes</b> Except 9&10mm (do not need high pressure)	No	No	No
Balloon diameter	Up to 10 mm	Up to 10 mm	Up to 7	Up to 12 mm

Data kindly provided by Dr Matteo Tozzi

## APERTO OTW<sup>®</sup> registry data show high rates of freedom from restenosis with APERTO OTW<sup>®</sup> in a real–world scenario




Kaplan-Meyer plot of freedom from restenosis after Aperto angioplasty

150 patients and 176 stenosis treated under conditions of actual clinical practice

Data kindly provided by Dr Matteo Tozzi, Varese, Italy

## How in China? A RCT Study



## Aperto AVF China Trial

Study Design:

Prospective, multicenter, randomized, controlled trial

- Device:
  - Treatment group: APERTO OTW<sup>®</sup> balloon (Paclitaxel Releasing Hemodialysis Shunt Balloon Dilatation Catheter)
  - Control group: OHICHO II balloon (Balloon Dilatation Catheter)
- Statistic design: Superiority

- Primary Endpoints (6 month):
  Primary patency rate of the target lesion at 6 month post procedure
- Secondary Endpoints:
  - Device Success (intraoperative)
  - Technical Success (intraoperative)
  - Clinical Success (at 1 month post procedure)
  - Clinical-driven Target Lesion Revascularization (CD-TLR, 12 month)
  - Clinical-driven Target Shunt Revascularization (CD-TSR, 12 month)
  - Major Adverse Event rate (MAE, including stroke, all-cause death and thrombosis at the target lesion site, 12 month)

## CASE

### Before angioplasty




### After angioplasty



### Follow-up 12 m









## Conclusions

- The China Aperto trial is the first multicenter randomized controlled trial to evaluate the safety and efficacy of APERTO OTW<sup>®</sup> compared with POBA for the treatment of AVF stenosis
- The final results will be available at CIRSE 2018

Thank you for your attention

Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (APERTO OTW®) for Arteriovenous Fistulae Stenosis: a Prospective, Multicenter, Randomized Controlled Trial APERTO AVF China

**Qizhuang Jin** 

Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China